BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, Narkewicz MR. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. Journal of Cystic Fibrosis 2017;16:139-45. [DOI: 10.1016/j.jcf.2016.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Guimbellot JS, Taylor-Cousar JL. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med 2021;9:677-9. [PMID: 33965001 DOI: 10.1016/S2213-2600(21)00176-4] [Reference Citation Analysis]
2 Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros 2019;18:838-43. [PMID: 31053538 DOI: 10.1016/j.jcf.2019.03.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
3 Galante GJ. Defining and Treating Cystic Fibrosis Liver Disease: Some Things Old and Some Things New. J Cyst Fibros 2022;21:199-201. [PMID: 35337600 DOI: 10.1016/j.jcf.2022.03.004] [Reference Citation Analysis]
4 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. Journal of Cystic Fibrosis 2017;16:S50-61. [DOI: 10.1016/j.jcf.2017.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
5 Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respir Med 2021:S2213-2600(21)00069-2. [PMID: 33965000 DOI: 10.1016/S2213-2600(21)00069-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sismanlar Eyuboglu T, Dogru D, Çakır E, Cobanoglu N, Pekcan S, Cinel G, Yalçın E, Kiper N, Sen V, Selimoglu Sen H, Ercan O, Keskin O, Bilgic Eltan S, Alshadfan L, Yazan H, Altıntas DU, Sasihuseyinoglu AS, Sapan N, Cekic S, Cokugraş H, Kılınc AA, Ramaslı Gursoy T, Aslan AT, Bingol A, Başaran AE, Ozdemir A, Kose M, Hangul M, Emiralioglu N, Tugcu G, Yuksel H, Yılmaz O, Orhan F, Gayretli Aydın ZG, Topal E, Tamay Z, Suleyman A, Can D, Bal CM, Caltepe G, Ozcelik U. Clinical features and accompanying findings of Pseudo‐Bartter Syndrome in cystic fibrosis. Pediatr Pulmonol 2020;55:2011-6. [DOI: 10.1002/ppul.24805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2021. [PMID: 34473419 DOI: 10.1002/ppul.25660] [Reference Citation Analysis]
8 Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 2021:S0168-8278(21)02115-2. [PMID: 34678405 DOI: 10.1016/j.jhep.2021.09.042] [Reference Citation Analysis]
9 Mcnamara JJ, Mccolley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine 2019;7:325-35. [DOI: 10.1016/s2213-2600(18)30460-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 15.7] [Reference Citation Analysis]
10 Siegel MJ, Freeman AJ, Ye W, Palermo JJ, Molleston JP, Paranjape SM, Stoll J, Leung DH, Masand P, Karmazyn B, Harned R, Ling SC, Navarro OM, Karnsakul W, Alazraki A, Schwarzenberg SJ, Seidel FG, Towbin A, Alonso EM, Nicholas JL, Murray KF, Otto RK, Sherker AH, Magee JC, Narkewicz MR; CFLD Network. Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study. J Pediatr 2020;219:62-69.e4. [PMID: 32061406 DOI: 10.1016/j.jpeds.2019.12.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
11 Galante G, Freeman AJ. Gastrointestinal, Pancreatic, and Hepatic Manifestations of Cystic Fibrosis in the Newborn. Neoreviews 2019;20:e12-24. [PMID: 31261070 DOI: 10.1542/neo.20-1-e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
13 Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018;34:146-51. [PMID: 29438119 DOI: 10.1097/MOG.0000000000000432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
14 Ling SC, Ye W, Leung DH, Navarro OM, Weymann A, Karnsakul W, Freeman AJ, Magee JC, Narkewicz MR. Liver Ultrasound Patterns in Children With Cystic Fibrosis Correlate With Noninvasive Tests of Liver Disease. J Pediatr Gastroenterol Nutr 2019;69:351-7. [PMID: 31436672 DOI: 10.1097/MPG.0000000000002413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zarei K, Meyerholz DK, Stoltz DA. Early intrahepatic duct defects in a cystic fibrosis porcine model. Physiol Rep 2021;9:e14978. [PMID: 34288572 DOI: 10.14814/phy2.14978] [Reference Citation Analysis]
16 Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 2018;6:545-53. [PMID: 29886024 DOI: 10.1016/S2213-2600(18)30202-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 31] [Article Influence: 25.5] [Reference Citation Analysis]
17 van de Peppel IP, Bertolini A, Jonker JW, Bodewes FAJA, Verkade HJ. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease. Curr Opin Pulm Med 2017;23:562-9. [PMID: 28837442 DOI: 10.1097/MCP.0000000000000428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
18 Sasame A, Stokes D, Bourke B, Connolly L, Fitzpatrick E, Rowland M. The impact of liver disease on mortality in cystic fibrosis-A systematic review. J Cyst Fibros 2021:S1569-1993(21)01328-X. [PMID: 34380590 DOI: 10.1016/j.jcf.2021.07.014] [Reference Citation Analysis]
19 Dana J, Girard M, Debray D. Hepatic manifestations of cystic fibrosis. Curr Opin Gastroenterol 2020;36:192-8. [PMID: 32097175 DOI: 10.1097/MOG.0000000000000624] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Karnsakul W, Wasuwanich P, Ingviya T, Vasilescu A, Carson KA, Mogayzel PJ, Schwarz KB. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease.J Cyst Fibros. 2020;19:546-552. [PMID: 32482593 DOI: 10.1016/j.jcf.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]